Investors & Media

Transformative science, targeted medicines

We are working to advance a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC Filings

SEC Filings

Filing date	Form	Description	View
Nov 05, 2018	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-18-012562.pdf 0001179110-18-012562.rtf
Nov 05, 2018	3	Initial filing by director officer or owner of more than ten percent.	View HTML 0001179110-18-012561.pdf 0001179110-18-012561.rtf
Nov 07, 2018	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-18-012637.pdf 0001179110-18-012637.rtf
Nov 15, 2018	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-18-009374.pdf 0001558370-18-009374.rtf 0001558370-18-009374.xls
Nov 21, 2018	4	Statement of changes in beneficial ownership of securities	View HTML 0001179110-18-013049.pdf 0001179110-18-013049.rtf
Dec 03, 2018	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-18-009542.pdf 0001558370-18-009542.rtf 0001558370-18-009542.xls
Jan 07, 2019	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-19-000064.pdf 0001558370-19-000064.rtf 0001558370-19-000064.xls
Feb 04, 2019	SC 13G/A	An amendment to the SC 13G filing	View HTML 0000215457-19-003235.pdf 0000215457-19-003235.rtf
Feb 05, 2019	8-K	Report of unscheduled material events or corporate event	View HTML 0001558370-19-000364.pdf 0001558370-19-000364.rtf 0001558370-19-000364.xls
Feb 11, 2019	SC 13G/A	An amendment to the SC 13G filing	View HTML 0000932471-19-004984.pdf 0000932471-19-004984.rtf 0000932471-19-004984.xls

Continue